



## Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025

Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2025 Annual General Meeting will be held on Tuesday, June 24, 2025 at 01:00 p.m. (CEST) at the Amsterdam offices of NautaDutilh N.V.

The full agenda and all relevant documents are available on the Company's website: <https://www.vivoryon.com/2025-annual-general-meeting/>.

###

### About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. [www.vivoryon.com](http://www.vivoryon.com)

### Vivoryon Forward Looking Statements

*This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a*



*result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.*

**For more information, please contact:**

**Investor Contacts**

**Vivoryon Therapeutics N.V.**

Dr. Manuela Bader, Director IR & Communication

Email: [IR@vivoryon.com](mailto:IR@vivoryon.com)

**LifeSci Advisors**

Sandya von der Weid

Tel: +41 78 680 05 38

Email: [svonderweid@lifesciadvisors.com](mailto:svonderweid@lifesciadvisors.com)

**Media Contact**

**Trophic Communications**

Valeria Fisher or Verena Schossmann

Tel: +49 175 8041816 / +49 151 219 412 77

Email: [vivoryon@trophic.eu](mailto:vivoryon@trophic.eu)